In a single-arm, open-label phase I trial (n = 18), researchers first used an intracerebroventricular (ICV) injection of dual-targeted EGFR/IL13Rα2 CAR-T cells to treat recurrent GBM(NCT05168423). Here, EGFR is linked to glioblastoma.